US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00%
FinancialContent

Articles published by AtaiBeckley Inc.

News headline image
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
From AtaiBeckley Inc.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets
From AtaiBeckley Inc.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations
From AtaiBeckley Inc.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
From AtaiBeckley Inc.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
From AtaiBeckley Inc.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
From AtaiBeckley Inc.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
From AtaiBeckley Inc.
Via GlobeNewswire
News headline image
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
From AtaiBeckley Inc.
Via GlobeNewswire
Tickers ATAI
News headline image
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
From AtaiBeckley Inc.
Via GlobeNewswire
Tickers ATAI
News headline image
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
From AtaiBeckley Inc.
Via GlobeNewswire
Tickers ATAI
News headline image
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
From AtaiBeckley Inc.
Via GlobeNewswire
Tickers ATAI